Zions Bancorporation’s Fate Therapeutics FATE Stock Holding History

Zions Bancorporation’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-63	Closed	-$636	–	963
2022 Q4	$636	Buy	+63	New	+$1.18K	﹤0.01%	1022

Other funds holding FATE

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Zions Bancorporation's FATE Position: Q1 2023 in Review

Zions Bancorporation sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 63 shares — an estimated $636 sold.

Zions Bancorporation first reported a position in FATE in Q4 2022 and held it in 1 quarter. The position peaked at $636 in Q4 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

Zions Bancorporation reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
Zions Bancorporation sold 63 Fate Therapeutics shares in Q1 2023, an estimated $636.
Zions Bancorporation first reported a position in Fate Therapeutics in Q4 2022 and held it in 1 quarter.
Zions Bancorporation's Fate Therapeutics position peaked at $636 in Q4 2022.
181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Zions Bancorporation's 13F filing for Q1 2023, filed 10 May 2023.